WAVE Life Sciences (FRA:1U5) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1U5 WAVE Life Sciences Ltd FRA:1U5
59 GF Score
Price €5.00
GF Value €3.66
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is WAVE Life Sciences Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

WAVE Life Sciences's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

FRA:1U5 vs CGEM, LXRX, XNCR: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, WAVE Life Sciences's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WAVE Life Sciences Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's Margin of Safety % (DCF Dividends Based) falls into.


FRA:1U5
59GF Score
WAVE Life Sciences Ltd FRA:1U5
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is WAVE Life Sciences (FRA:1U5) Overvalued in 2026?

Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued. The current stock price of €5.00 is trading 36.6% above its estimated GF Value™ of €3.66. GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.

Key valuation signals for FRA:1U5:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €3.66 vs. price of €5.00 (36.6% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the FRA:1U5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WAVE Life Sciences Business Description

Other Exchanges WVE:USA1U5:Germany
Address 7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score

Get the complete analysis for FRA:1U5

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.00
Price
€3.66
GF Value